Výsledky vyhledávání - "Debbie Swinarski"

Abstract 1756: Discovery and characterization of AB680, a potent and selective small-molecule CD73 inhibitor for cancer immunotherapy

Autor: Matt J. Walters, Fang-Fang Yin, Debbie Swinarski, Jenna L. Jeffrey, Lixia Jin, Jarek Kalisiak, Ada Chen, Kenneth V. Lawson, Powers P. Jay, Steve Young, Ulrike Schindler, Kristen Zhang

Publikováno v: Cancer Research. 78:1756-1756

Introduction. Extracellular adenosine (ADO) suppresses immune function via inhibition of T cell and NK cell activation and is present in high concentrations in the tumor micro-environment (TME). Intra-tumoral generation of ADO depends on the sequenti

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::fcefe9cf0a1ef2f30da54903469f4468
https://doi.org/10.1158/1538-7445.am2018-1756

Zobrazit plný text záznamu

CHIR-258 is efficacious in a newly developed fibroblast growth factor receptor 3-expressing orthotopic multiple myeloma model in mice

Autor: Suzanne Trudel, Yan Tang, Katherine Rendahl, Carla Heise, Dirk B. Mendel, Paul Hollenbach, Nancy Pryer, Tinya Abrams, Bahija Jallal, Debbie Swinarski, Xiaohua Xin, Yoko Oei, Millicent Embry, Evelyn N. Garrett

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research. 12(16)

Purpose: The ectopically expressed and deregulated fibroblast growth factor receptor 3 (FGFR3) results from a t(4;14) chromosomal translocation that occurs in ∼15% of multiple myeloma (MM) patients and confers a particularly poor prognosis. This st

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b9d59a3f5f673717d679b2a31498c996
https://pubmed.ncbi.nlm.nih.gov/16914579

Zobrazit plný text záznamu

Abstract B104: The orally bioavailable proteasome inhibitor PR-047 inhibits metastasis in a mouse mammary carcinoma model

Autor: Jing Jiang, Tony Muchamuel, Mark K. Bennett, Debbie Swinarski, Christopher J. Kirk

Publikováno v: Molecular Cancer Therapeutics. 8:B104-B104

Background: Proteasome inhibitors, such as bortezomib and the tetrapeptide epoxyketone carfilzomib, have shown strong antitumor activity in patients with multiple myeloma and mantle cell lymphoma. Anti-tumor responses are due to direct tumor cell cyt

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4502e97169eaabdceb8307bb969420d1
https://doi.org/10.1158/1535-7163.targ-09-b104

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání